N/A
N=402
HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma
Bottom Line
View on ClinicalTrials.gov: NCT03483922 ↗Enrolled (actual)
402
Serious AEs
—
Results posted
Jul 2024
Primary outcome: Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- ctDNA methylation in and it's Correlation wth Development and prediction of HCC (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- HKGepitherapeutics
- Primary completion
- Jun 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Calculation of M Scores and HCC Probability Scores |
1.113; 1.159; 1.797; 1.707; 1.839; 1.818 | — |
Summary
Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship. Follow up of high-risk populations such as chronic hepatitis patients and early diagnosis of transitions from chronic hepatitis to HCC would improve cure rates. In most cases HCC is detected late resulting in increased mortality and morbidity.
The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in hepatocellular carcinomas patients.
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of HCC by EASL-EORTC guidelines
- Confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines.
Exclusion Criteria for HCC:
- Cirrhosis, any other known inflammatory disease (bacterial or viral infection with the exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid disease) which could alter T cells and monocytes characteristics
- Other cancers.
Exclusion Criteria for HepB:
- Diagnosis of HCC or any other cancer.
Exclusion Criteria for Healthy Controls:
- Any known inflammatory or infectious disease including HepB and HepC
- Chronic diseases,
- Cancer
- Medications or drug use
Data sourced from ClinicalTrials.gov (NCT03483922). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.